ReviewAntibodies (Basel, Switzerland)2024
Diagnosis and Management of Catastrophic Antiphospholipid Syndrome and the Potential Impact of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
Review in Antibodies (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Article
- Rare Pediatric Male Presentation of Systemic Lupus Erythematosus With Catastrophic Antiphospholipid Syndrome Following Pulmonary Tuberculosis: A Case Report.Clinical case reports · 2026Article
- Catastrophic Antiphospholipid Syndrome in a Young Female Complicated by Systemic Lupus Erythematosus and Left Atrial Myxoma: A Rare Case Report.Clinical case reports · 2026Article
- Article
- Probable Catastrophic Antiphospholipid Syndrome Overlapping Hematological Abnormalities: A Case Report.Clinical case reports · 2026Article
- Catastrophic antiphospholipid syndrome in a 39-year-old woman.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Article
- Catastrophic antiphospholipid syndrome complicated with multiple infections: a case report.Frontiers in immunology · 2026Article
- Catastrophic Antiphospholipid Syndrome: A Rare but Life-Threatening Thrombotic Storm-A Case Report and Literature Review.Case reports in rheumatology · 2026Article
- Cardiovascular Disorders in Systemic Lupus Erythematosus.Current vascular pharmacology · 2026Review
- Case report of a fatal probable catastrophic antiphospholipid syndrome.Frontiers in medicine · 2026Article
- Role of antiphospholipid antibodies in kidney disease: Risk factors, immunopathogenesis, and diagnosis.World journal of nephrology · 2025Review
- Antiphospholipid Syndrome and the Kidney.Kidney international reports · 2025Review
- Complement activation in secondary thrombotic microangiopathies.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Systemic Lupus Erythematosus with Refractory Immune Thrombocytopenia Progressing to Catastrophic Anti-Phospholipid Syndrome During Thrombopoietin Receptor Agonist Therapy: A Case Report.Journal of clinical medicine · 2025Article
- Article
- Pathological Study of a Case of Catastrophic Antiphospholipid Syndrome in a Patient With Gastrointestinal Bleeding.Cureus · 2025Article
- Catastrophic antiphospholipid syndrome presenting with a stroke as a first presentation: case report.Oxford medical case reports · 2025Article
- Article
- β2GPI-targeted polymeric nanoparticles form a protective layer to prevent vascular thrombosis in an anti-phospholipid syndrome model.Frontiers in immunology · 2025Article
- Case Report: Failure of eculizumab to block complement to prevent relapse of anti-phospholipid syndrome in kidney transplant recipient.Frontiers in nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catastrophic antiphospholipid syndrome (CAPS) is a rare and life-threatening condition characterized by the persistence of antiphospholipid antibodies and occurrence of multiple vascular occlusive events. CAPS currently remains a diagnostic challenge and requires urgent treatment. The diagnosis of CAPS is made difficult by classification criteria used as diagnostic criteria in clinical practice, knowledge derived from retrospective data and case reports, confounding clinical and biological features, and its rapid onset and mortality. The absence of prospective studies of CAPS limits the strength of evidence for guideline treatment protocols. This comprehensive review summarizes the current understanding of the disease, and discusses how the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria impact the definition and therapeutic management of CAPS, which is considered the most severe form of APS. The correct integration of 2023 ACR/EULAR APS classification criteria is poised to facilitate CAPS diagnosis, particularly in critical situations, offering a promising avenue for improved outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.